Durata Therapeutics Inc (DRTX) 15.17 $DRTX
Nasdaq stocks posting largest percentage increases
AP - Mon Aug 04, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report).
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 7:30AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) has scheduled its quarterly conference call for Thursday, August 7 at 8:30 a.m. Eastern Time to discuss second quarter 2014 financial results.
Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries, which include Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey, and Commonwealth of Independent States.
United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:37AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise more than 8% on the day
Durata Therapeutics unveils DALVANCE for injection for treating acute bacterial skin and skin structure infections
M2 - Mon Jul 21, 6:59AM CDT
Pharmaceutical company Durata Therapeutics (NasdaqGM RTX) disclosed on Monday the market availability of DALVANCE (dalbavancin) for injection for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI).
Investing to Fight Toilet and Elevator Superbugs
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Jul 19, 2:00PM CDT
A big thank-you to our friends at FierceHealthcare for an incredible story about how a recent study indicated that hospital elevator buttons might have a higher prevalence of bacteria colonization than toilets. Yes, you read that correctly....
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
GlobeNewswire - Fri Jul 18, 6:59AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) announced today that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI). DALVANCE was approved by the U.S. Food and Drug Administration (FDA) on May 23, 2014 and was the first drug approved as a Qualified Infectious Disease Product (QIDP). Durata began shipping DALVANCE to its distributors earlier this week. Physicians and Pharmacists may now order DALVANCE from ASD Healthcare or their wholesaler, or they may call Durata at 1 855 DURATA1 (1-855-387-2821).
Cubist and Durata Heat Up Antibiotic Market
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Antibiotics are on a comeback. And Cubist Pharmaceuticals is in the middle of it. Gone are the days when it seemed the Food and Drug Administration had a bone to pick with every antibiotic drugmaker. On Friday, the agency approved its second...
Cubist Gains FDA Approval for Sivextro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:50AM CDT
Cubist's (CBST) Sivextro gained FDA approval for the ABSSSI indication.
FDA approves Cubist antibiotic for skin infections
By MATTHEW PERRONE - AP - Fri Jun 20, 5:32PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.
Durata Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Jun 17, 8:00AM CDT
Durata Therapeutics (Nasdaq RTX) announced today that members of the executive team will participate in three upcoming investor conferences.
3 Reasons Why Shorts Are Moving into Durata Therapeutics
George Budwell, The Motley Fool - Motley Fool - Fri Jun 13, 9:42AM CDT
Because short-sellers are exposed to potentially unlimited losses, they tend to be cautious in choosing their targets. So whenever the short interest picks up in a stock, it's important to understand why. Durata Therapeutics has seen a rapidly...
New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program
GlobeNewswire - Wed Jun 04, 4:00PM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) today announced the Phase 3 data from its DISCOVER program evaluating dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults was the subject of an article published in the latest edition of the New England Journal of Medicine (NEJM), "Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection." The complete article is now available online to subscribers at www.nejm.org and will appear in the June 5 print edition. The article highlights the benefits of dalbavancin and its potential to change the treatment paradigm for ABSSSI patients.
This Week in Biotech: VIVUS Attracts Buyout Interest While BioCryst Wows Investors
Sean Williams, The Motley Fool - Motley Fool - Sat May 31, 10:25AM CDT
With the SPDR S&P Biotech Index up 18% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
1 Stock Fighting the Rise of Deadly Superbugs
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
A potentially devastating public health crisis has been developing over the past 30 years and surprisingly little has been done to avert it. I'm referring to the evolution of "superbugs," or multidrug resistant strains of microbes like infectious...
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed May 28, 6:45PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Nasdaq stocks posting largest percentage increases
AP - Mon Aug 04, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report). 3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 7:30AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) has scheduled its quarterly conference call for Thursday, August 7 at 8:30 a.m. Eastern Time to discuss second quarter 2014 financial results. Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries, which include Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey, and Commonwealth of Independent States. United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:37AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise more than 8% on the day
Durata Therapeutics unveils DALVANCE for injection for treating acute bacterial skin and skin structure infections
M2 - Mon Jul 21, 6:59AM CDT
Pharmaceutical company Durata Therapeutics (NasdaqGM
RTX) disclosed on Monday the market availability of DALVANCE (dalbavancin) for injection for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI). Investing to Fight Toilet and Elevator Superbugs
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Jul 19, 2:00PM CDT
A big thank-you to our friends at FierceHealthcare for an incredible story about how a recent study indicated that hospital elevator buttons might have a higher prevalence of bacteria colonization than toilets. Yes, you read that correctly....
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
GlobeNewswire - Fri Jul 18, 6:59AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) announced today that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI). DALVANCE was approved by the U.S. Food and Drug Administration (FDA) on May 23, 2014 and was the first drug approved as a Qualified Infectious Disease Product (QIDP). Durata began shipping DALVANCE to its distributors earlier this week. Physicians and Pharmacists may now order DALVANCE from ASD Healthcare or their wholesaler, or they may call Durata at 1 855 DURATA1 (1-855-387-2821). Cubist and Durata Heat Up Antibiotic Market
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Antibiotics are on a comeback. And Cubist Pharmaceuticals is in the middle of it. Gone are the days when it seemed the Food and Drug Administration had a bone to pick with every antibiotic drugmaker. On Friday, the agency approved its second...
Cubist Gains FDA Approval for Sivextro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:50AM CDT
Cubist's (CBST) Sivextro gained FDA approval for the ABSSSI indication.
FDA approves Cubist antibiotic for skin infections
By MATTHEW PERRONE - AP - Fri Jun 20, 5:32PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.
Durata Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Jun 17, 8:00AM CDT
Durata Therapeutics (Nasdaq
RTX) announced today that members of the executive team will participate in three upcoming investor conferences. 3 Reasons Why Shorts Are Moving into Durata Therapeutics
George Budwell, The Motley Fool - Motley Fool - Fri Jun 13, 9:42AM CDT
Because short-sellers are exposed to potentially unlimited losses, they tend to be cautious in choosing their targets. So whenever the short interest picks up in a stock, it's important to understand why. Durata Therapeutics has seen a rapidly...
New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program
GlobeNewswire - Wed Jun 04, 4:00PM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) today announced the Phase 3 data from its DISCOVER program evaluating dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults was the subject of an article published in the latest edition of the New England Journal of Medicine (NEJM), "Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection." The complete article is now available online to subscribers at www.nejm.org and will appear in the June 5 print edition. The article highlights the benefits of dalbavancin and its potential to change the treatment paradigm for ABSSSI patients. This Week in Biotech: VIVUS Attracts Buyout Interest While BioCryst Wows Investors
Sean Williams, The Motley Fool - Motley Fool - Sat May 31, 10:25AM CDT
With the SPDR S&P Biotech Index up 18% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
1 Stock Fighting the Rise of Deadly Superbugs
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
A potentially devastating public health crisis has been developing over the past 30 years and surprisingly little has been done to avert it. I'm referring to the evolution of "superbugs," or multidrug resistant strains of microbes like infectious...
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed May 28, 6:45PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
